"id:ID","uuid","bcCategories","documentVersion","name","studyDesignRationale","description","studyEstimands","label","id","studyInvestigationalInterventions"
"820","ee527c72-599a-4f91-8a53-cdc3156e56bb","[]","","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","[]","","StudyDesign_1","[]"
